# Xeris Biopharma Holdings (XERS) Stock Analysis: Potential 100% Upside Beckons Investors

- Link: https://www.directorstalkinterviews.com/xeris-biopharma-holdings-xers-stock-analysis-potential-100-upside-beckons-investors/4121246803
- Published: 2026-03-27T11:10:10+00:00
- Author: Madison Wilson

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is capturing investor attention with
a potential upside of 100.05%, as highlighted by recent analyst ratings. This Chicago-
based biopharmaceutical company is dedicated to advancing treatments for chronic
endocrine and neurological diseases, making it a prominent player in the healthcare
sector.

Currently trading at $5.57, Xeris Biopharma has a market capitalization of $960.44
million. The stock has experienced a modest price change of 0.27 (0.05%) and sits
within a 52-week range of $3.95 to $9.90. Despite these fluctuations, the company’s
growth potential remains a focal point for investors, particularly given its impressive
revenue growth of 42.80%.

A noteworthy aspect of Xeris Biopharma’s financial profile is the absence of a trailing
P/E ratio, which is offset by a forward P/E of 15.03. This forward-looking valuation
metric suggests that the company is expected to achieve profitability in the near
future, a promising sign for investors seeking growth opportunities in the biotechnology
industry.

Xeris’s robust product portfolio, including Gvoke for severe hypoglycemia, Keveyis
for primary periodic paralysis, and Recorlev for Cushing’s syndrome, underscores
its potential for sustained revenue growth. Moreover, the ongoing phase 3 clinical
trial for XP-8121, a treatment for hypothyroidism, could further bolster the company’s
market position if successful.

From a technical standpoint, Xeris Biopharma’s 50-day moving average is $6.55, and
its 200-day moving average is $6.90, both above the current trading price. The Relative
Strength Index (RSI) of 23.73 suggests that the stock is in oversold territory, 
which might indicate a buying opportunity for contrarian investors. Additionally,
the MACD and Signal Line are both in negative territory, which could signal a potential
reversal or continuation of the current trend depending on future market movements.

Analysts have largely favorable views on Xeris Biopharma, with 6 buy ratings and
only 1 hold rating, and no sell recommendations. The target price range for XERS
is set between $8.00 and $18.00, with an average target price of $11.14. This suggests
significant upside potential compared to its current trading price, making it an
attractive option for investors with an appetite for risk.

Despite these promising indicators, investors should remain mindful of the inherent
risks associated with investing in biopharmaceutical companies, including regulatory
hurdles, clinical trial outcomes, and market competition. However, Xeris Biopharma’s
strategic focus on niche therapeutic areas and its advancing pipeline provide a 
compelling investment thesis for those looking to capitalize on the healthcare sector’s
growth trajectory.

As Xeris Biopharma continues to innovate and expand its product offerings, the company
stands poised to capture further market share. Investors seeking exposure to the
biotechnology sector may find XERS to be a valuable addition to their portfolios,
particularly given its potential for significant upside and strong analyst support.

Share on: